---
schema_version: "secwatch.filing_event.v1"
accession: "0001658247-26-000020"
form_type: "8-K"
ticker: "CRNX"
cik: "0001658247"
company_name: "Crinetics Pharmaceuticals, Inc."
filed_at: "2026-03-23T23:59:59+00:00"
generated_at: "2026-05-15T09:22:21.704902+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Crinetics' Chief Development and Operating Officer resigns effective April 10, 2026

## Summary
- Jeff Knight resigns as Chief Development and Operating Officer, effective April 10, 2026.
- Resignation is to pursue another opportunity; not related to any disagreement with the Company.
- No successor named; Knight's duties and direct reports reassigned to other executive leadership team members.

## SEC filing metadata
- accession: 0001658247-26-000020
- form_type: 8-K
- ticker: CRNX
- cik: 0001658247
- company_name: Crinetics Pharmaceuticals, Inc.
- filed_at: 2026-03-23T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1658247/000165824726000020/0001658247-26-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1658247/000165824726000020/crnx-20260317.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001658247-26-000020
- JSON: https://secwatch.observer/filing/0001658247-26-000020.json
- Plain text: https://secwatch.observer/filing/0001658247-26-000020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.